Combination Therapy for Bladder Cancer

Inquiry

Bladder cancer remains one of the most prevalent and challenging malignancies, with a significant impact on patient outcomes worldwide. At Alfa Cytology, our dedicated team of biologists and oncology experts has been at the forefront of exploring innovative combination therapies to address this critical healthcare concern.

Introduction to Combination Therapy

Bladder cancer is the 9th most commonly diagnosed cancer globally, with an estimated 430,000 new cases and 150,000 deaths each year. While recent breakthroughs in immunotherapy and targeted therapies have brought new hope, the road to optimal treatment remains paved with challenges. Specifically, the low response rates and the emergence of drug resistance have prompted the scientific community to investigate combination strategies that can overcome these limitations.

Ongoing Clinical Trials of Novel Combination Therapies for Bladder Cancer

Trial ID	Eligibility	Phase	Combination Therapy
NCT01928394	Advanced or metastatic bladder cancer	Phase l/ll	Nivolumab and lpilimumab
NCT03084471	Advanced bladder cancer	Phase lll	Duralumab and Tremelimumab
NCTO3219775	Metastatic or advanced transitional cell carcinoma	Phase ll	Nivolumab and lpilimumab
NCT03036098	Unresectable or metastatic UC	Phase lll	Nivolumab, lpilimumab, Gemcitabine / Cisplatin / Carboplati
NCTO2516241	Unresectable stage lV UC	Phase lll	Duralumab and Tremelimumab
NCTO4223856	Advanced or metastatic UC	Phase lll	EV and Pembrolizumab
NCTO3519256	BCG unresponsive high-risk NMIBC	Phase ll	Nivolumab, BMS-986205 and BCG
NCTO2560636	Advanced bladder cancer	Phase l	Pembrolizumab and radiotherapy
NCTO2643303	Bladder cancer	Phase l/ll	Tremelimumab, Durvalumab and polyICLC
NCT03473743	Metastatic or adyanced UC	Phase lb/ll	Erdafitinib, Cetrelimab and Platinum

Our Services

At Alfa Cytology, we offer a comprehensive suite of preclinical services to support the development of novel combination therapies for bladder cancer. We provide a wide range of services tailored to the development of combination therapies and beyond.

Combination Immunochemotherapy
Combination of Radiotherapy with Targeted Therapy
Synergistic Ferroptosis-starvation Therapy
Combination of Photodynamic Therapy (PDT) with Immunotherapy

Combination of Sonodynamic Therapy (SDT) with Chemotherapy
Combination Chemo-photodynamic Therapy
Combination of Chemodynamic Therapy (CDT) with Photothermal Therapy (PTT)
And More

Our services include but are not limited to:

Robust in vitro and in vivo tumor model development and characterization

Detailed mechanistic investigations of synergistic combination regimens

Cutting-edge pharmacology and pharmacokinetic studies

Comprehensive preclinical efficacy and safety evaluations

Contact Us

To learn more about our groundbreaking work in combination therapy for bladder cancer or to explore potential collaboration opportunities, please don't hesitate to contact us at Alfa Cytology. Our team of experts is ready to engage in productive discussions and explore how we can work together to revolutionize the treatment landscape for this devastating disease.

Reference

Peng M., Xiao D., and et al. Novel Combination Therapies for the Treatment of Bladder Cancer. Front. Oncol. 2021, 10: 539527.

For research use only. Not intended for any clinical use.

Related Services

Solutions

Inquiry

* Name:

* Email:

Phone:

* Services:

Description:

* Please note that we are not a pharmacy or clinic, so we do not offer diagnostic and treatment services for patients.

* Tick to confirm the Research Use Only (RUO) statement.